期刊文献+

肺癌患者胸腔积液中CEA及CA153的表达及意义 被引量:10

Expression and significance of CEA and CA153 in pleural fluid of patients with lung cancer
下载PDF
导出
摘要 背景与目的常规细胞学查找肺癌患者胸腔积液中的癌细胞始终是难点。本研究拟通过检测肺癌患者血清和胸腔积液中癌细胞释放的癌蛋白,以弥补单纯细胞学检测的局限性,寻找一种更灵敏、准确的肺癌检测手段。方法采用化学发光分析仪对74例肺癌患者及34例非肺癌患者的血清和胸腔积液进行了免疫蛋白定量分析。结果肺癌组胸腔积液内CEA及CA153水平明显高于非肺癌组内水平(P<0.01);肺癌组血清内CEA及CA153水平亦明显高于非肺癌组内水平(P<0.01);肺癌组胸腔积液内CEA及CA153水平明显高于其血清内水平(P<0.01);在胸腔积液中,CEA与CA153联合检测为最佳组合,其敏感性和特异性分别高达85.1%和97.1%。结论检测肺癌患者胸腔积液中CEA及CA153水平可能对肺癌的诊断具有重要的临床意义。 Background and objective Finding the cancer cells in pleural fluid of patients with lung cancer by conventional cytology is always a difficult point. In order to enhance the diagnostic rate of pleural fluid with lung cancer, carcinoembryonic antigen (CEA) and cancer antigen 153 (CA153) were detected in serum and pleural fluid, and their diagnostic values on lung cancer were analyzed. Methods Quantities of CEA and CA153 were detected by chemiluminescence in both serum and pleural fluid of patients with lung cancer (74 cases) and without lung cancer (34 cases). Results The levels of CEA and CA153 in pleural fluid of patients with lung cancer were significantly higher than those without lung cancer (P〈0.01). The levels of CEA and CA153 in serum of patients with lung cancer were distinctly higher tb.an those without lung cancer (P〈0.01 ). The levels of CEA and CA153 in pleural fluid were obviously higher than those in serum (P〈0.01). The optimal diagnostic assay of lung cancer was CEA+CA153 combination., sensitivity and specificity were 85.1 % and 97. 1% respectively. Conclusion It could be of important clinical significance for diagnosing lung cancer by assaying CEA and CA153 in pleural fluid of patients with lung cancer.
出处 《中国肺癌杂志》 CAS 2006年第4期337-339,共3页 Chinese Journal of Lung Cancer
基金 辽宁省教委科研项目基金(No.2004D164)资助~~
关键词 肺肿瘤 胸腔积液 细胞诊断学 Lung neoplasms Pleural effusion Cytodiagnosis
  • 相关文献

参考文献9

  • 1Shitrit D, Zingerman B, Shitrit AB, et al. Diagnostic value of CYFRA 21 1, CEA, CA 19-9, CA 15-3, and CA 125 assays in pleural effusions: analysis of 116 cases and review of the literature. Oncologist,2005,10(7) : 501-507.
  • 2Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem,2000,33(5) : 405-410.
  • 3Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA,CA 15 3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer,2001,31(1) : 9 16.
  • 4Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer,1999,81(6) : 1059-1065.
  • 5Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non small cell lung cancer. Anticancer Res,2001,21(4B) : 3085-3092.
  • 6Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen,squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem, 2002,48(11):1931-1937.
  • 7Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest,2004,126(6) : 1757-1763.
  • 8Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.Chest,2005,128(4):2298-2303.
  • 9吴广平,巴静,王恩华,滕月娥,范霞.检测胸水中CEA、CA125、CA153及CA199对肺癌的诊断价值[J].中国肺癌杂志,2004,7(1):35-37. 被引量:75

二级参考文献8

  • 1[1]Fuhrman C, Duche JC, Chouaid C, et al. Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem,2000,33(5):405-410.
  • 2[2]Alatas F, Alatas O, Metintas M, et al. Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions. Lung Cancer,2001,31(1):9-16.
  • 3[3]Miedouge M, Rouzaud P, Salama G, et al. Evaluation of seven tumor markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer,1999,81(6):1059-1065.
  • 4[4]Ando S, Kimura H, Iwai N, et al. Optimal combination of seven tumor markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res,2001,21(4B):3085-3092.
  • 5[5]Kulpa J, Wojcik E, Reinfuss M, et al. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem,2002,48(11):1931-1937.
  • 6[6]Salgia R, Harpole D, Herndon JE 2nd, et al. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res,2001,21(2B):1241-1246.
  • 7[9]Romero S, Fernandez C, Arriero JM, et al. CEA, CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions. Eur Respir J,1996,9(1):17-23.
  • 8[10]Toumbis M, Rasidakis A, Passalidou E, et al. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions. Anticancer Res,1996,16(4A):2101-2104.

共引文献74

同被引文献57

引证文献10

二级引证文献134

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部